PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

BACKGROUND: Multiple myeloma (MM) is a malignant plasma cell disease with a poor survival, characterized by the accumulation of myeloma cells (MMCs) within the bone marrow. Epigenetic modifications in MM are associated not only with cancer development and progression, but also with drug resistance....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Epigenetics
Hlavní autoři: Herviou, Laurie, Kassambara, Alboukadel, Boireau, Stéphanie, Robert, Nicolas, Requirand, Guilhem, Müller-Tidow, Carsten, Vincent, Laure, Seckinger, Anja, Goldschmidt, Hartmut, Cartron, Guillaume, Hose, Dirk, Cavalli, Giacomo, Moreaux, Jerome
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171329/
https://ncbi.nlm.nih.gov/pubmed/30285865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-018-0554-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky